Keros Announces Return of $375 Million in Excess Capital to Stockholders

Core Viewpoint - Keros Therapeutics has concluded its strategic alternatives review and plans to return $375 million of excess capital to stockholders while continuing the development of its lead product candidate, KER-065, for neuromuscular diseases, particularly Duchenne muscular dystrophy [1][2]. Group 1: Strategic Review and Capital Return - The Board of Directors unanimously decided to initiate a process to return $375 million of excess capital to stockholders following a comprehensive review of strategic alternatives [1][2]. - The strategic review included evaluating various options such as a potential sale of the company, continued investment in the pipeline, and returning excess capital to stockholders [2]. Group 2: Product Development Focus - Keros is focused on the development of KER-065 for treating neuromuscular diseases, with an initial emphasis on Duchenne muscular dystrophy, reflecting the company's confidence in its potential benefits [2][4]. - The company is also advancing its product candidate elritercept (KER-050) for treating cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndrome and myelofibrosis [4].